{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Overall response rate of participants after completing tandem transplant. Overall Response rate defined as the composite endpoint of response to treatment which includes Complete Response (CR), Partial Response (PR), stable disease (SD) as defined in International Response Criteria.","groups":[{"description":"Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma\n\nBortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1","id":"OG000","title":"Tandem Transplantation With Melphalan and Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"94 participant response assessed after completion of tandem transplant","reportingStatus":"POSTED","timeFrame":"3 years","title":"To Determine the Response Rate of Patients With Multiple Myeloma Treated With High-dose Melphalan or High-dose Melphalan in Combination With Bortezomib Given in Tandem Transplants.","type":"SECONDARY","unitOfMeasure":"Participants"}